IPSU

Item no.	HY-13796-5mg
Manufacturer	MedChem Express
CASRN	1373765-19-5
Amount	5 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Metabolism Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Betschart C, et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleeparchitecture for the treatment of insomnia. J Med Chem. 2013 Oct 10;56(19):7590-607.\|[2]Callander GE, et al. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci. 2013 Dec 3;7:230.\|[3]Hoyer D, et al. Distinct effects of IPSU and suvorexant on mouse sleep architecture.
Smiles	COC1=CC=NC(N(CC2)CCC2(C3=O)CCCN3CC4=CNC5=CC=CC=C54)=N1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1373765-19-5
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Orexin Receptor (OX Receptor)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	405.49
Product Description	IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pKi of 7.85.
Manufacturer - Research Area	Neurological Disease; Endocrinology
Solubility	DMSO: ≥ 30 mg/mL
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Isoform	OX2 Receptor
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13796-5mg-safety-datasheet.pdf